FHL1 and cardiac hypertrophy: Finally, we tested several biomarkers for cardiac hypertrophy and immunoblots (Fig. 2f), which showed increased (P < 0.01) protein levels for α-ACTININ (153 ± 16% Tmem65 KD hearts; 100 ± 13% control hearts), cardiac troponin T (cTnT; 178 ± 20% Tmem65 KD hearts; 100 ± 16% control hearts), four-and-half LIM domain 1 (FHL1; 788 ± 153% Tmem65 KD hearts; 100 ± 12% control hearts), β-myosin heavy chain (MYH7; 187 ± 37% Tmem65 KD hearts; 100 ± 16% control hearts), and phosphorylated extracellular signal-regulate kinases 1/2 (p-ERK1/2, 159 ± 21% Tmem65 KD hearts; 100 ± 22% control hearts).